Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/ mL in people with type 2 diabetes in China: A post‐hoc analysis of the INITIATION study
Authors' conclusion
Gla-300 improved glycaemic control with a low risk of hypoglycaemia in Chinese people with T2D across all ages and disease durations, including older individuals and those with long-standing diabetes.
Study context
- Population
- Chinese adults with uncontrolled T2D (HbA1c 7.5%-11.0%) receiving Gla-300
- Participants
- 568 adults
- Comparison
- Gla-300 outcomes by baseline age and disease duration subgroups
- Insulin-naïven = 191
- Prior BIn = 377
- Primary endpoint
- HbA1c change from baseline
- Follow-up
- Week 24
Methodological details24-week
- 24-week
Primary result
As reported in the abstract
24 weeks
Insulin-naïve: LS mean HbA1c change range
−1.02% (−11.1 mmol/mol) to −1.55% (−16.9 mmol/mol)
Prior BI: LS mean HbA1c change range
−0.55% (−6.0 mmol/mol) to −0.76% (−8.3 mmol/mol)
Further findings
HbA1c <7.0% (<53 mmol/mol) achievement, other glycaemic endpoints, insulin dose increases, body weight changes, DTSQ score improvements
- HbA1c <7.0% achievement range across subgroups
- 19.5% to 40.7%
- Did not significantly differ across the majority of subgroups
Safety
- Hypoglycaemia risk remained low
Original publication
Effects of age and disease duration on the glycaemic outcomes and safety of insulin glargine 300 U/ mL in people with type 2 diabetes in China: A post‐hoc analysis of the INITIATION study. Diabetes Obes Metab. Published 5 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →